Sumitomo Mitsui Trust Group Inc. Sells 35,215 Shares of Illumina, Inc. $ILMN

13 Apr 2026, 05:50 by Scott Moore · The Cerbat Gem

Sumitomo Mitsui Trust Group Inc. lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,254,595 shares of the life sciences company’s stock after selling 35,215 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Illumina were worth $164,553,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Illumina by 7.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after acquiring an additional 79 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after acquiring an additional 96 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Illumina by 4.2% during the 4th quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock worth $323,000 after acquiring an additional 99 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of Illumina by 8.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock worth $130,000 after acquiring an additional 111 shares in the last quarter. Finally, Archer Investment Corp boosted its stake in shares of Illumina by 12.9% during the 3rd quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after acquiring an additional 123 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Analysts highlight Illumina’s strong earnings-surprise history and say the company currently has the characteristics that make another quarterly beat likely — a bullish near-term earnings catalyst that can support the stock ahead of the April 30 report. Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? Zacks: Will Illumina (ILMN) Beat Estimates Again?
Neutral Sentiment: Illumina confirmed it will report Q1 2026 results after the close on Thursday, April 30, with a management conference call scheduled — a clear near-term event that could drive volatility depending on revenue/guide vs. expectations. Illumina to Announce First Quarter 2026 Financial Results
Neutral Sentiment: Market coverage notes recent share-price strength (outperformance since Oct‑2025) but also that Illumina still lags broader market measures on some timeframes — useful context for momentum and relative-performance trades. MarketWatch: Illumina stock rises, still underperforms market
Neutral Sentiment: A valuation/peer piece compares Illumina to Regeneron as potential value plays in the biomedical/genetics space — useful for investors weighing sector alternatives but not an immediate directional catalyst. REGN or ILMN: Which Is the Better Value Stock Right Now?
Negative Sentiment: A Seeking Alpha analysis argues that competitive threats (new platforms, pricing pressure) are an ongoing headwind and may already be reflected in the stock — a cautionary take that can temper upside expectations and increase sensitivity to execution. Illumina: Competitive Threats Priced In
Negative Sentiment: A recent “3 Reasons to Avoid ILMN” article outlines concerns (valuation after the run, execution/risks) that may be driving some profit‑taking and cautious positioning despite recent strong results. 3 Reasons to Avoid ILMN and 1 Stock to Buy Instead

Illumina Price Performance

NASDAQ ILMN opened at $120.93 on Monday. Illumina, Inc. has a twelve month low of $69.83 and a twelve month high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The stock has a market capitalization of $18.37 billion, a PE ratio of 22.19, a P/E/G ratio of 2.32 and a beta of 1.49. The stock has a 50-day simple moving average of $123.95 and a 200 day simple moving average of $123.65.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on ILMN shares. Barclays upped their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Canaccord Genuity Group boosted their price objective on Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. Robert W. Baird set a $137.00 price objective on Illumina in a research report on Friday, February 6th. Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 14th. Finally, Stifel Nicolaus boosted their price objective on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $129.69.

Check Out Our Latest Analysis on ILMN

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This represents a 12.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.17% of the stock is currently owned by company insiders.

About Illumina

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.